Brokers Set Expectations for Gilead Sciences Q1 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for Gilead Sciences in a report released on Monday, November 4th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will earn $1.63 per share for the quarter, up from their prior forecast of $1.62. The consensus estimate for Gilead Sciences’ current full-year earnings is $3.75 per share. Zacks Research also issued estimates for Gilead Sciences’ Q3 2025 earnings at $2.04 EPS, Q4 2025 earnings at $1.80 EPS, Q1 2026 earnings at $1.62 EPS and Q3 2026 earnings at $2.11 EPS.

Other equities analysts have also issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, October 9th. Wells Fargo & Company upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $78.00 to $100.00 in a report on Monday, October 7th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Finally, Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Ten research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $86.85.

Gilead Sciences Trading Up 0.4 %

GILD stock opened at $90.22 on Wednesday. The company has a market capitalization of $112.32 billion, a PE ratio of 110.02, a price-to-earnings-growth ratio of 3.12 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences has a one year low of $62.07 and a one year high of $90.71. The company’s 50 day moving average price is $84.32 and its two-hundred day moving average price is $74.55.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.61 by $0.40. The firm had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently made changes to their positions in the stock. Plato Investment Management Ltd grew its stake in shares of Gilead Sciences by 5.1% in the third quarter. Plato Investment Management Ltd now owns 50,821 shares of the biopharmaceutical company’s stock worth $4,257,000 after acquiring an additional 2,468 shares during the last quarter. D Orazio & Associates Inc. bought a new position in Gilead Sciences in the 3rd quarter worth about $245,000. Oppenheimer Asset Management Inc. grew its position in Gilead Sciences by 0.5% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 184,172 shares of the biopharmaceutical company’s stock valued at $15,441,000 after purchasing an additional 948 shares during the last quarter. Carrera Capital Advisors increased its stake in Gilead Sciences by 23.6% during the 3rd quarter. Carrera Capital Advisors now owns 25,546 shares of the biopharmaceutical company’s stock valued at $2,142,000 after purchasing an additional 4,886 shares in the last quarter. Finally, Aptus Capital Advisors LLC raised its holdings in Gilead Sciences by 3.9% in the third quarter. Aptus Capital Advisors LLC now owns 8,263 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 309 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,847 shares of company stock valued at $3,033,340. 0.29% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.